Should immunotherapy be standard of care for metastatic MSI-high colorectal cancer?   

It should be a treatment option but not yet in the first line. My first option for MSI-H patients is to enroll in an immunotherapy trial. If not available, I'll usually reserve  single-agent PD-1 inhibitors until after second line therapy. Recent data suggests that the Ipilimumab-nivolumab comb...